Trial Profile

A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary)
Indications Plaque psoriasis
Focus Registrational; Therapeutic Use
Acronyms STELLAR-2
Sponsors Biocon Biologic

Most Recent Events

12 Mar 2025 According to a Biocon Biologics media release, data from this trial was presented at 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
07 Mar 2025 Results presented in the Biocon Biologics media release media release.
07 Mar 2025 According to a Biocon Biologics media release, The U.S. FDA approved YESINTEK in December 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com